



3712 E. Plano Parkway, Ste. 200
Plano, TX 75074

This prescription form is to be sent & received via fax

Dermatology Injectable Enrollment Form A-D

Physician Offices Call:
855-460-7928

Fax: 888-777-5645

Prescriber:	NPI:
Supervising Physician:	NPI:
Address:	Tax ID:
Phone:	Fax:
Contact:	

PATIENT INFORMATION

Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State: ____	ZIP: ____-____
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION

Has the patient received a loading dose/starter kit? Yes Start Date: ____/____/____ No SHIP TO: Patient's Home Doctor's Office Other: _____

Drug	Directions & Quantity	Refills
Bimzelx® <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Autoinjector	<input type="checkbox"/> INITIAL: Inject 320 mg (two 160 mg injections) SQ on week 0, 4, 8, 12, and 16 (Quantity: 10) <input type="checkbox"/> MAINTENANCE: Inject 320 mg (two 160 mg injections) SQ every 8 weeks (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 320 mg (two 160 mg injections) SQ every 4 weeks (Quantity: 2) ***Intended for patients ≥ 120 kg (264 lbs)***	
Cimzia® <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Vials	<input type="checkbox"/> Inject 400 mg SQ every other week (Quantity: 4) <input type="checkbox"/> INITIAL: Inject 400 mg (two 200 mg injections) SQ on week 0, 2, 4 (Quantity: 6) ***Intended for patients ≤ 90 kg (198 lbs)*** <input type="checkbox"/> MAINTENANCE: Inject 200 mg SQ every other week starting on week 6 (Quantity: 2)	
Cosentyx® <input type="checkbox"/> Sensoready® Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Sensoready® Pen <input type="checkbox"/> UnoReady® Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 150 mg SQ on week 0, 1, 2, 3, and 4 (Quantity: 5) <input type="checkbox"/> MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1) <input type="checkbox"/> INITIAL: Inject 300 mg SQ on week 0, 1, 2, 3, and 4 (Quantity: QS 5 doses) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: QS 28 days) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 2 weeks (Quantity: QS 28 days) ***Intended for HS patients who did not adequately respond to Q4W dosing***	
Dupixent® <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 600 mg SQ (two 300 mg injections) at week 0 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)	

MEDICAL INFORMATION

*****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY*****

PREVIOUS THERAPIES: <input type="checkbox"/> Methotrexate <input type="checkbox"/> Soriatane <input type="checkbox"/> Clobetasol <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: _____	<p>Affected Areas</p> <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____ BSA % PASI Score
PHOTOTHERAPY <input type="checkbox"/> UVA /UVB <input type="checkbox"/> Patient cannot afford	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: _____	
<input type="checkbox"/> L28.1 Prurigo Nodularis <input type="checkbox"/> L73.2 Hidradenitis suppurativa	<input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> Other: _____	Date of Diagnosis: ____/____/____		
Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____ Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____				

Additional Clinical Information:

American Academy of Dermatology Consensus Statement on Psoriasis Therapies

- Psoriasis is covering greater than 10% of body surface area
- Psoriasis is on palms, soles, head and neck, or genitalia
- Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
- Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships

INJECTION TRAINING

- Patient has received pen and injection training
- Physician's office to provide injection training
- Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____ **Date:** ____/____/____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.